The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
ARD Podcast
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Listen on:
Episodes
Friday Mar 06, 2020
Friday Mar 06, 2020
Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early Arthitis Cohort (PEAC), Rivellese at al could show that B cell-rich synovitis is associated with disease severity and radiographic progression, in particular, if B cell infiltrates persist after cDMARD treatment.
Tuesday Feb 18, 2020
Tuesday Feb 18, 2020
This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.
Thursday Jan 23, 2020
Thursday Jan 23, 2020
Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.
Monday Dec 23, 2019
Monday Dec 23, 2019
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
Tuesday Dec 10, 2019
Tuesday Dec 10, 2019
TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.
Thursday Aug 22, 2019
Thursday Aug 22, 2019
The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess the potential of drug repurposing in three rheumatic diseases. This has the potential to identify genes which are functionally relevant and the target of existing therapies, which could provide new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.
Friday Jul 12, 2019
Friday Jul 12, 2019
The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence, are discussed in this podcast.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.
Monday Jun 03, 2019
Monday Jun 03, 2019
Musculoskeletal diseases have increased significantly between 2000 and 2015 and are now the second cause of years lived with disability worldwide, a study recently published by ARD concludes. The paper also adds that the burden is higher in Europe.
“The richest the country, the highest the burden of musculoskeletal diseases”, says the leading author. Professor Laurent Arnaud and Dr Eden Sebbag(Department of Rheumatology - Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, France) discuss the details of the study with ARD's Social Media Advisor, Dr Paul Studenic.
Read the full paper: https://ard.bmj.com/content/78/6/844.
Wednesday Aug 29, 2018
Wednesday Aug 29, 2018
Find out how to increase your chances of a successful submission in this very short podcast with Annals of the Rheumatic Diseases’s Associate Editor Francis Berenbaum. He is interviewed by the Social Media Advisor of the journal, Christophe Richez.
Read more information for authors on the ARD website: https://ard.bmj.com/pages/authors/.
Submit your manuscript here: https://mc.manuscriptcentral.com/ard.
Tuesday Jul 10, 2018
Tuesday Jul 10, 2018
A study that compares the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis recruited 10 years apart is discussed in this podcast. The results from the UK’s Norfolk Arthritis Register are shared by two of its co-authors from the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester Academic Health Science Centre: James Gwinnutt and Suzanne Verstappen (NIHR Manchester Biomedical Research Centre) in conversation with the social media advisor for ARD Meghna Jani.
Read the full paper on the Annals of the Rheumatic Diseases website: https://ard.bmj.com/content/77/6/848.